Drug products: Livocab, Livostin
ATC code: R01AC02, S01GX02
Substances: levocabastine, levocabastine hydrochloride
There are no published controlled studies on differences between the sexes regarding efficacy, safety and pharmacokinetics of levocabastine.
Levocabastine is topically used in allergic rhinoconjunctivitis as a nasal spray or eye drops [1,2]. The prevalence of self-reported allergic rhinoconjunctivitis symptoms in a Swedish population study (n=10,670) was similar in men and women . In a large population-based cohort study of self-reported rhinitis performed in 13 countries (150 378 male person-years, 163 363 female person-years) 27,7% of participants reported rhinitis. The peak incidence time was in adolescence, in both males and females. In atopic subjects, the incidence of rhinitis was slightly higher in males in childhood but higher in females after the age of 25 .
Bioavailability after intranasal administration is 60-80% [1,4] and in ophtalmic administration 30-60% (2,4). Due to the low doses that are given, low plasma concentrations have been reported after topical administration .
No clinically significant age- or sex-related differences in steady-state levocabastine concentrations have been reported in patients with allergic rhinitis and allergic conjunctivitis treated with levocabastine topically, according to a review article (data not shown) .
No studies with a clinically relevant sex analysis regarding effects of levocabastine have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of levocabastine have been found.
Date of litterature search: 2022-08-04
Reviewed by: Diana Rydberg, Pauline Raaschou, Carl-Olav Stiller
Approved by: Karin Schenck-Gustafsson